Genetics of coronary heart disease: Current knowledge and research principles

American Heart Journal

Volumn 140, Issue 4, 2000, Pages

  Winkelmann, B R ^a   Hager, J ^a   Kraus, W E ^a   Merlini, P ^a   Keavney, B ^a   Grant, P J ^a   Muhlestein, J B ^a   Granger, C B ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; CORONARY RISK; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENOTYPE; ISCHEMIC HEART DISEASE; MEDICAL GENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 0033819588     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2000.109636     Document Type: Conference Paper

References (101)

1. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project - Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents
2. Genetic architecture of common multifactorial diseases
3. Genetic susceptibility to death from coronary heart disease in a study of twins
4. A genome based resource of molecular cardiovascular medicine
5. Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome
6. Sequence diversity in 36 candidate genes for cardiovascular disorders
7. Characterization of single-nucleotide polymorphisms in coding regions of human genes
8. Apolipoprotein B-gene DNA polymorphisms associated with myocardial infarction
9. Apolipoprotein polymorphisms fail to define risk of coronary artery disease - Results of a prospective, angiographically controlled study
10. DNA polymorphisms of the apolipoprotein B gene are associated with altered plasma lipoprorein concentrations but not with perceived risk of cardiovascular disease: European Atherosclerosis Research Study
11. Apolipoprotein E polymorphism and atherosclerosis
12. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease
13. Association of apolipoprotein E polymorphism, low density lipoprotein cholesterol, and coronary artery disease
14. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease - The Framingham Offspring Study
15. Common variation in the lipoprotein lipase gene: Effects on plasma lipids and risk of atherosclerosis
16. Identification of putative benficial mutations for lipid transport
17. A common substitution (Asn291 Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease
18. Lipoprotein lipase variants D9N and N291S are associated with increased plasma triglyceride and lower high-density lipoprotein cholesterol concentrations - Studies in the fasting and postprandial states: The European Atherosclerosis Research Studies
19. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease
20. Heterogeneity at the CETP gene locus - Influence on plasma CETP concentrations and HDL cholesterol levels
21. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis
22. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene
23. The pathogenesis of atherosclerosis - An update
24. The pathogenesis of atherosclerosis: A perspective for the 1990s
25. Role of hemostatic gene polymorphisms in venous and arterial thrombolic disease
26. Increased binding of fibrinogen to glycoprotein Illa proline33 (HPA-1b, PLa2, Zwb) positive platelets in patients with cardiovascular disease
27. Increased platelet aggregability associated with platelet GPIIla Pla2 polymorphism-the Framingham Offspring study
28. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis
29. Polymorphism of platelet membrane glycoprotein Illa: Human platelet antigen (HPA-1b/PLa2) is an inherited risk factor for premature myocardial infarction in coronary artery disease
30. Prothrombolic genetic risk factors in young survivors of myocardial infarctior
31. The Leu33/Pro polymorphism (PLa 1/a2) of the glycoprotein Illa (GPIIla) receptor is not related to myocardial infarction in the ECTIM study
32. A1/A2 polymorphism of glycoprotein a and association with excess procedural risk for coronary catheter interventions: A case-controlled study
33. PLa 1/a2 polymorphism of platelet glycoprotein Illa and risks of myocardial infarction, stroke, and venous thrombosis
34. Hereditary variation in platelet integrin a2a1 density is associated with two silent polymorphisms in the a2 gene coding sequence
35. Association of the plalelet glycoprotein la C807T gene polymorphism with nonfatal myocardial infarction in younger patients
36. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart study
37. Elevated plasma fibrinogen - Cause or consequence of cardiovascular disease
38. Fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction
39. Positive association of the fibrinogen H1/H2 gene variation to basal fibrinogen levels and to the increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction
40. European Atherosclerosis Research Study: Genotype at the fibrinogen locus (G-455A b-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe - Evidence for gender-genotype-environment interaction
41. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction
42. Contribution of factor VII genotype to activated FVII levels - Differences in genotype frequencies between Northern and Southern European populations
43. Polymorphisms of factor V, factor VII, and fibrinogen genes - Relevance to severity of coronary artery disease
44. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men
45. Factor VII arg/Gln-353 polymorphism determines fator VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study
46. Factor VII gene polymorphism and cardiovascular disease: The Framingham Heart Study
47. Gene polymorphisms predicting high plasma levels of coagulation and fibrinolysis proteins - A study in centenarians
48. Increased plasma levels of a rapid inhibitor of plasminogen activator inhibitor in young survivors of myocardial infarction
49. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction
50. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography
51. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study
52. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men
53. Association of a common polymorphism in the factor XIII gene with myocardial infarction
54. The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity
55. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
56. An insertion/deletion polymorphism in the angiotensin I-converting gene accounting for half the variance of serum levels
57. Deletion polymorphism in the angiotensin-converting enzyme is a potent risk factor for myocardial infarction
58. Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease
59. ACE gene polymorpohism: Ischemic heart disease and longevity in 10150 individuals - A case-referent and retrospective cohort study based on the Copenhagen City Heart Study
60. No association of the I/D polymorphism of the angiotensin-converting enzyme with myocardial infarction in 4941 probands
61. Large-scale test of hypothesized associations between the angiotensin-I converting enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 5000 controls
62. Association studies of genetic polymorphisms and complex disease
63. Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training
64. Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training
65. Molecular genetics of human hypertension: Role of angiotensinogen
66. Association between the angiotensinogen 235T-variant and essential hypertension in whites - A systematic review and methodological appraisal
67. Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease
68. Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease
69. Genetic variation at the angiotensinogen locus in relation to high blood pressure and myocardial infarction: The ECTIM study
70. Associations between candidate loci angiotensin-converting enzme and angiotensinogen with coronary heart disease and myocardial infarction: The NHLBI Family Heart Study
71. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease
72. 677T mutation, plasma homocysteine, folate in subjects from northern Italy with and without angiographically documented severe coronary atherosclerotic disease: Evidence for an important genetic-environmental interaction
73. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease
74. 677T gene polymorphism is asssociated with the extent of coronary atherosclerosis in patients at high risk for coronary artery diease
75. 677T mutation
76. Variation at the promoter of the fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers
77. Coronary heart disease and genetics: An epidemiologist's view
78. Genetic and environmental correlations among serum lipids and apolipoproteins in elderly twins reared together and apart
79. Evidence that the apolipoprotein E-genotype effects on lipid levels can change with age in males: A longitudinal analysis
80. Sex differences in coronary heart disease - Why are women so superior [The 1995 Ancel Keys Lecture]
81. Interpretation of results from genetic studies of multifactorial diseases
82. Freely associating
83. Apolipoprorein E genotype: Epsilon32 women are protected while epsilon43 and epsilon44 men are susceptible to ischemic heart disease - The Copenhagen City Heart Study
84. Some thoughts on clinical trials, especially problems of multiplicity
85. A simple approximation for calculating sample sizes for comparing independent groups
86. The future of genetic studies of complex human diseases
87. Molecular and statistical approaches to detection and correction of errors in genotype databases
88. Strategies for the assessment of genetic coronary artery disease risk
89. Biologic complexity and strategies for finding DNA variations responsible for inter-individual variation in risk of common chronic disease, coronary artery disease
90. Application of cladistics to the analysis of genotype-phenotype relationships
91. Haplotype structure and population genetic inferences from nucleotide-sequence variation in human lipoprotein lipase
92. Genetic epidemiology
93. Genetics of complex disease - Approaches, problems, and solutions
94. The future of genetic association studies in hypertension: Improving the signal-to-noise ratio
95. The practical problems of post-genomic biology
96. Making genomic medicine a reality [1998 ASHG presidential adress]
97. Waiting for the working draft from the human genome project
98. Will genetics revolutionize medicine?
99. Genetic variation in coronary heart disease and myocardial infarction: Methodological overview and clinical evidence